News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Xenova Group PLC (XNVA) Licenses DISC-HSV And DISC-GM-CSF Vector Technologies To Oxxon Therapeutics Inc.; $83 Million; Stock Up



10/19/2005 5:12:16 PM

BOSTON--(BUSINESS WIRE)--Jan. 13, 2005--Oxxon Therapeutics, Inc. announced today that Oxxon has licensed exclusive worldwide rights to Xenova Group's plc (NASDAQ: XNVA and London Stock Exchange: XEN) DISC-HSV and DISC-GM-CSF vector platforms for use in developing products for certain major cancers and chronic infectious diseases. DISC-GM-CSF, used as a stand-alone product, has been tested in a number of oncology indications including a dose-ranging Phase I trial for melanoma.

Read at BioSpace.com
Read at Prime Zone

Related News

comments powered by Disqus
   
Melanoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES